ANIP vs AZN: fair value comparison
ANI Pharmaceuticals, Inc. and AstraZeneca PLC · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. AZN carries the stronger quality grade. AZN carries the stronger momentum grade.
| ANIP | AZN | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $80.06 | $156.93 |
| 12-month range | $75.22–$94.10 | $156.06–$202.39 |
| Sector rank | #11 of 113 Healthcare | #6 of 113 Healthcare |
| Quality grade | C- | B |
| Momentum grade | B | A |
| Leverage | Moderate | Moderate |
| Margin trend | — | Expanding |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ANIP fair value analysis · AZN fair value analysis